Overview of the trastuzumab (Herceptin) anti-HER2 monoclonal antibody clinical program in HER2-overexpressing metastatic breast cancer. Herceptin Multinational Investigator Study Group (Q33730978)
scientific article
Language:
Current Data About Overview of the trastuzumab (Herceptin) anti-HER2 monoclonal antibody clinical program in HER2-overexpressing metastatic breast cancer. Herceptin Multinational Investigator Study Group
(P31) (Q13442814)
(P248)
(P698) 10482196
(P813) Saturday, July 29, 2017

(P304) 71-77
(P248)
(P698) 10482196
(P813) Saturday, July 29, 2017

(P433) 4 Suppl 12
(P248)
(P698) 10482196
(P813) Saturday, July 29, 2017

(P478) 26
(P248)
(P698) 10482196
(P813) Saturday, July 29, 2017

(P577) Sunday, August 1, 1999
(P248)
(P698) 10482196
(P813) Saturday, July 29, 2017

(P921) (Q61643320)
(P887)

(Q79460)
(P887)

(Q412616)
(P887)

(Q422248)
(P887)

(P1433) (Q14330412)
(P248)
(P698) 10482196
(P813) Saturday, July 29, 2017

(P1476) "Overview of the trastuzumab (Herceptin) anti-HER2 monoclonal antibody clinical program in HER2-overexpressing metastatic breast cancer. Herceptin Multinational Investigator Study Group" (language: en)
(P248)
(P698) 10482196
(P813) Saturday, July 29, 2017

(P2093) S Shak
(P1545) 1
(P248)
(P698) 10482196
(P813) Saturday, July 29, 2017

(P13046) (Q7318358)
(P248)

other details
description scientific article

External Links
(P698) 10482196